NTRK1 and cancer: In thefuture, the combination of PPARγ ligands with kinase inhibition selectively targeted by MABs against theEGFR tyrosine receptor kinase family or LMW selective inhibitors of thedownstream ERK cascade, such as Raf and MEK, may constitute a possible newapproach to treat cancer.